March 10th 2025
Adovate Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030 for the Treatment of C. Difficile Infections
This is the second Virginia Catalyst award to develop Adovate’s breakthrough therapies. Charlottesville, VA – March 10, 2025 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing drug candidates targeting the adenosine receptors, today announced